© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
May 20, 2010
The FDA concludes that the cholesterol-lowering drugs simvastatin (Zocor),ezetimibe (Zetia), and Vytorin (ezetimibe/simvastatin)
are not likely to increase cancer risk.
According to data from a French study, patients with unresectable metastatic colorectal cancer who experience a chemotherapy-free interval (CFI) following first-line chemotherapy have shorter durations of disease control(DDC)and progression-free survival (PFS) compared with patients who begin maintenance therapy immediately.
According to a multi-institutional study, terminally ill cancer patients are more likely to seek hospice care and less likely to pursue aggressive end-of-life (EOL) treatment if the medical team supports their spiritual needs.
Emily Strouphauer, BSA: Linking Pediatric Psoriasis to Anxiety, Depression
Raj Chovatiya, MD, PhD: Psoriasis Treatment Developments, FDA Approvals in 2022
Lawrence Eichenfield, MD: Phase 3 Trial Data on Ruxolitinib for Atopic Dermatitis